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Abstract
Respiratory tract infection, especially pneumonia, is a significant cause of morbidity and
mortality worldwide. Although rapid and accurate identification of the pathogens and
the corresponding treatment, which is based on the microbiological results, is required
in the healthcare setting, the current clinical tests lack high sensitivity and flexibility. As
of yet, a comprehensive approach has not been able to work these issues out. Meanwhile,
the development of  molecular techniques enables the detection of organisms from
respiratory specimens speedily as well as precisely and aids the settlement of such
issues. With our novel approach that employs relative quantification, we successfully
set the cutoff value to discriminate the causative pathogen from colonizing commensal
organisms by real-time PCR. In this way, a diagnostic system for respiratory pathogens
was devised and validated through clinical sample testing. In this chapter, a real-time
PCR-based test capable of differentiating causative pathogens in respiratory specimens
is described, and also its principle and the utility of this approach are illustrated.
Keywords: PCR, real-time PCR, pneumonia, respiratory tract infection, sputum,
HIRA-TAN, commensal organism, foreign organism, non-commensal organism, nu-
cleic acid amplification test, NAAT
1. Introduction
Pneumonia is a common disease in healthcare settings and is a significant cause of morbidity
and  mortality  worldwide.  Despite  there  being  a  mere  two-dozen  species  of  pathogens
responsible for most cases of pneumonia, the causative pathogen cannot be identified by
clinical tests involving smear and culture of sputum, antigen tests, and serological assays in
up to 50% of the cases [1–4]. Therefore, the identification of the causative pathogen(s) with
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high detection power will allow for the selection of targeted antibiotics. Accordingly, timely
identification has been shown to reduce the mortality rate and, on a long-term basis, the
emergence of drug-resistant pathogens [5]. To identify such pathogens and thus to obtain the
desired benefits, a clinical test is required that is sensitive, rapid, accurate, easily performed,
and cost-effective.
Figure 1. The overall strategy and assessment of pneumonia. The current consensus for diagnosis through treatment of
pneumonia was summarized by STEP1 through STEP6 [3, 4]. Although examples of assessment, such as CURB-65 for
CAP and ATS consensus for HAP, were illustrated in STEP3, an appropriate index ought to be chosen in each situation.
The development and wide usage of molecular techniques, such as polymerase chain reaction
(PCR), brought about remarkable advances in clinical medicine. Detection of causative
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pathogens in pneumonia has been optimized in the last few decades, and from that point, PCR
has played a principal role in laboratory medicine [6–8]. Currently PCR-based approaches,
however, are mainly used to identify foreign organisms (such as Mycoplasma pneumoniae or
Legionella pneumophila) in respiratory specimens [2, 9–11]. Even if such clinical tests have a
multiplex detection system, identification of foreign organisms alone shows limited clinical
value since the majority of pneumonia is caused by commensal organisms (such as Streptococ‐
cus pneumoniae or Haemophilus influenzae). Thus, distinguishing causative pathogens from
among detected commensal organisms in respiratory samples, which contain colonizing
organisms, has been challenging due to the highly sensitive detection power of PCR.
In this chapter, a real-time PCR-based test which is capable of differentiating therapeutic
targets from detected colonizing commensal organisms in respiratory samples is described,
and also its principle and the utility of this approach are illustrated.
2. Clinical approach and current strategy for pneumonia
Pneumonias are as of now classified as either the community-acquired pneumonia (CAP) or
the hospital-acquired pneumonia (HAP), depending on the place pneumonia is acquired
(Figure 1). Each has a specific spectrum of causative pathogens and allows medical professio-
nals to speculate on the causative pathogen and initiate empirical antimicrobial therapy
covering most of the speculated pathogens (Figure 2). Following confirmation of the causative
pathogen, the antimicrobial should be switched/de-escalated to more specific and appropriate
medication.
Figure 2. Etiology of three types of pneumonia diagnosed by conventional methods in clinical study. Five-hundred and
sixty eight patients were enrolled in the prospective study where seven institutions participated [12]. Three-hundred
and forty nine, 147, and 72 patients who met the criteria of pneumonia shown in Figure 1 were categorized as com-
munity-acquired pneumonia (CAP), healthcare-associated pneumonia (HCAP), and hospital-acquired pneumonia
(HAP), respectively, in which causative pathogen(s) were summarized in pie charts. In this study, all patients tested
Gram stain and culture of expectorated sputum, urine antigen for Streptococcus pneumoniae, and real-time PCR for My‐
coplasma pneumoniae, Chlamydophila pneumoniae, Chlamydophila psittaci, Coxiella burnetii, Legionella pneumophila, Bordetella
pertussis, Mycobacterium tuberculosis, Mycobacterium intracellulare, Mycobacterium avium, Mycobacterium kansasii, and
Pneumocystis jiroveci. Urine antigen was tested for in the case of L. pneumophila for admitted cases only and influenza
antigen for flu season only. Mixed infection indicates the cases in which two or more causative pathogens were identi-
fied at one time.
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3. Organisms in respiratory tract infection
3.1. Conventional diagnostic tools for causative pathogens
A wide variety of laboratory tests including culture-based methods, antigen tests, and serology
have been available for diagnosis and treatment of pneumonia (Table 1). Nevertheless, despite
comprehensive evaluations with a range of different tests, as many as 40% of the causative
pathogens causing CAP, HCAP, and HAP remain undiagnosed (Figure 2). While defining the
pathogenic role of the respiratory organisms during pneumonia is still difficult, a commensal
organism and foreign organism are often considered to be a causative pathogen when the
below criteria are met. These criteria have provided legitimate results and thus have been used
in clinical practice.
3.2. Commensal organism
Commensal organisms form part of human normal flora in the respiratory system (e.g.,
Streptococcus pneumoniae, Haemophilus influenzae, or Pseudomonas aeruginosa). However, in
specific situations as when the host defense is weakened, the number of organisms grows
beyond their typical ranges and then causes pneumonia. Since the majority of them reside in
the respiratory tract, when they are detected from respiratory sample, there is no unequivo-
cal criterion to discriminate causative pathogen from colonizing one by the sputum exami-
nation.
3.3. Foreign organism (non-commensal organism)
Foreign organisms account for a small portion of pneumonias (e.g., Mycoplasma pneumoniae,
Legionella pneumophila, or Mycobacterium tuberculosis) (Figure 2). They do not reside in the
respiratory tract or are rarely identified from healthy individuals, and thus their detection
indicates that they are the causative pathogens.
3.4. Criteria for commensal organisms to be the causative pathogen
A commensal organism that fulfills at least one of the following three criteria is consid-
ered to be a causative pathogen when (1) an organism is identified from the normally
sterile site (blood or pleural effusion); (2) a morphologically compatible organism, coex-
isting with abundant neutrophils, is observed through Gram staining and later confirmed
by sputum culture; or (3) for Streptococcus pneumoniae only, the urine antigen test is posi-
tive.
3.5. Criteria for foreign organisms to be the causative pathogen
Foreign organisms that fulfill at least one of the following two criteria are considered to be a
causative pathogen when (1) an organism is identified by culture, antigen test (involving
serum, urine or nasopharyngeal specimen), or PCR test or (2) a paired serological test reveals
a significant increase in antibody titer (more than four times).
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Rapid test Confirmed diagnosis
Commensal organisms
Gram-positive cocci
 Streptococcus pneumoniae Gram stain, urine antigen Culture
 Streptococcus milleri group Culture
 Staphylococcus aureus Gram stain Culture
Gram-negative cocci
 Moraxella catarrhalis Gram stain Culture
Gram-negative rods
 Haemophilus influenzae Gram stain Chocolate agar culture
(Non-fermenter)
 Pseudomonas aeruginosa Gram stain Culture
 Acinetobacter baumannii Culture
 Stenotrophomonas maltophilia Culture
 Burkholderia cepacia Selective agar culture
(Enterobacteria)
 Klebsiella pneumoniae Gram stain Culture
 Escherichia coli Culture
 Serratia marcescens Culture
Anaerobes
Anaerobes Gram stain from sterile sample Anaerobic culture
Foreign organisms
Atypical organisms
 Mycoplasma pneumoniae NAAT Serology CF, PPLO culture
 Legionella pneumophila NAAT, urine antigen BCYE culture
 Chlamydophila pneumoniae NAAT Serology MIF
 Chlamydophila psittaci NAAT Serology MIF
 Coxiella burnetii NAAT Serology IIF
 Mycobacterium Tuberculosis NAAT, AFB smear Lowenstein-Jensen culture
Opportunistic organisms
 Actinomyces israelii Anaerobic culture, microscopy for sulfur granules
 Nocardia asteroides Gram stain, AFB smear Culture
 Pneumocystis jiroveci NAAT, Giemsa stain
Fungi
 Aspergillus fumigatus GMS stain, Galactomannan test Sabouraud agar culture
 Cryptococcus neoformans Antigen test Sabouraud agar culture
 Histoplasma capsulatum Antigen test Serology CF, Sabouraud agar culture
 Coccidioides immitis Serology ID, Sabouraud agar culture
Viruses
Influenza virus NAAT, rapid antigen
Parainfluenza virus NAAT Serology EIA
RS virus NAAT, rapid antigen
 Human metapneumovirus NAAT Serology EIA
Adenovirus NAAT, antigen test
 Cytomegalovirus pp65 antigen
Parasites
Paragonimus westermani Microscopy for ova Microscopy for ova or worms
Representative laboratory tools to diagnose clinically significant pathogens which cause pneumonia are listed [13].
NAAT, nucleic acid amplification test; CF, complement fixation; PPLO, pleuropneumonia-like organism; BCYE,
buffered charcoal yeast extract; MIF, micro-immunofluorescence; IIF, indirect immunofluorescence; AFB, acid-fast
Bacillus; GMS, Gomori methenamine silver; ID, immunodiffusion; EIA, enzyme immunoassay.
Table 1. Current laboratory diagnosis of pathogens causing pneumonia.
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3.6. Issues with applying conventional diagnostic tools for identifying causative pathogens
in respiratory samples
Although an organism requires specific agar or a unique detection assay, applying such
different kinds of diagnostic tools for all patients with pneumonia is not practical and feasible
from the standpoint of labor required. Moreover, the most significant issue is the culture-based
method, which is a standard test for respiratory samples containing colonizing organisms or
normal flora. It is not capable of discriminating a causative pathogen from isolated commensal
organisms.
4. A real-time PCR for respiratory samples
4.1. Applying molecular techniques to identifying the causative pathogens in respiratory
tract infection
Nucleic acid amplification test (NAAT), such as a PCR-based test or reverse transcription-PCR
(RT-PCR), for purulent sputum is a logical and beneficial strategy. Firstly, if PCR cannot detect
a suspected pathogen, the pathogen is less likely to be the causative pathogen due to the highly
sensitive nature of PCR which can amplify even small numbers of pathogens. Secondly, PCR
is capable of identifying foreign organisms that cannot grow on the standard culture agar.
Thus, their detection conclusively yields the causative pathogens. Thirdly, PCR is a speedy
test, and the result can be delivered to medical professionals in an early phase of the treatment.
Finally, from the standpoint of NAAT, organisms causing respiratory tract infections can be
simply divided into two categories; commensal organism and foreign organism (see Sections
3.2 and 3.3). Therefore, PCR does not require the pathogen-specific agar or growth conditions
since all organisms are dealt with at the nucleic acid (DNA or RNA) level in the laboratory.
4.2. Issues with applying molecular diagnostic tools for identifying causative pathogens in
respiratory samples
A major problem associated with a PCR-based test, similar to conventional methods, is its
inability to discriminate a commensal organism causing pneumonia from the same organism
colonizing in the airway.
Given the unique aspect of sputum, we assumed that, although setting a cutoff value by the
direct quantification of bacterial cell number in respiratory samples would fluctuate and thus
provide indistinct discrimination between causative pathogen and colonizing organism, using
the relative quantification would be more stable even using the sputum which lacks homoge-
neity and reproductivity. To overcome this challenge, we proposed the “battlefield hypothe-
sis,” in which the ratio of pathogen to human cells in the respiratory samples would be an
indicator for the dominant pathogen in the “pneumonia battlefield.” The principal of this
hypothesis is that the relative number of combatants (i.e., pathogens) causing the current state
of pneumonia is considered a major determinant.
Polymerase Chain Reaction for Biomedical Applications106
Figure 3. Battlefield hypothesis. (A) When pneumonia occurs, the number of human inflammatory cells (gray) increas-
es at the inflammation site where that of the causative pathogen (blue) outnumbers the human cells. Meanwhile, the
colonizing pathogens (red) lag behind. Thus, the ratio of causative pathogen cells to human cells was considered as a
practical indicator for the discrimination of the causative pathogen from the colonizing organisms. (B) The ratio of cell
numbers between two cell types in sputum is measureable by quantitative PCR. The Ct (threshold cycle) is the number
of PCR cycles at which the fluorescent signal passes the threshold. Cthuman is the Ct for the human-specific gene,
Ctpathogen is the Ct for the pathogen-specific gene, and both are log proportional to the number of the cells during PCR
cycles, which is accordingly formulated to ΔCtpathogen = −(Ctpathogen − Cthuman). (C) Since ΔCtpathogen indicates the ratio of
pathogen cells to human cells, the ΔCtpathogen cutoff can be determined. Two examples of pneumonia cases were dis-
played; case A is Streptococcus pneumoniae (S. pneumoniae) pneumonia (Gram-positive cocci in purple), and case B is
Haemophilus influenzae (H. influenzae) pneumonia (Gram-negative bacilli in red). In case A, the ΔCtS. pneumoniae value above
which a pathogenic role of S. pneumoniae in pneumonia was confirmed should show a higher value, while a ΔCtS. pneumo‐
niae value would demonstrate lower value in case B in which H. influenzae dominated human cells and S. pneumoniae
played a colonizing role. (D) Determination of the ΔCtpathogen cutoff in a case of S. pneumoniae pneumonia. ΔCtpathogen was
measured for commensal organisms in a pilot study (n = 223). Respiratory samples from patients with pneumonia in
which S. pneumoniae was identified using commensal organism criteria (1)–(3) (see Section 3.4) were illustrated as blue
circles, and samples in which none of criteria (1)–(3) was met were depicted as white circles. The ΔCtS. pneumoniae cutoff (a
red line) was determined as the smallest ΔCtS. pneumoniae for the blue circles. Sputum in which S. pneumoniae was not de-
tected and ΔCtS. pneumoniae was not applied is shown at the bottom (shown as “not detected”).
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4.3. Battlefield hypothesis
With the battlefield hypothesis, the ratio of the cell number of a commensal organism to
human cell numbers is assumed to be an index of the organism’s pathogenic role. When
pneumonia occurs, the number of human cells, mostly inflammatory cells, drastically
climbs at the site of infection where that of causative pathogen exceeds the human cells
(Figure 3A). On the other hand, pathogens that merely colonize the affected area do not
proliferate. In a real-time PCR-based system specializing in quantification, the specific pri-
mers and probe can amplify the target sequence log proportionally, in which the ratio of
pathogen to human cells is formulated as ΔCtpathogen = −(Ctpathogen − Cthuman) (Figure 3B). As
indicated by the battlefield hypothesis, a threshold value that discriminates commensal or-
ganisms from organisms colonizing the airway would be set up as ΔCtpathogen cutoff (Fig-
ure 3C).
Figure 4. Determination of ΔCtpathogen cutoff. The ΔCtpathogen was measured for seven representative commensal organ-
isms from the past clinical study (n = 533, from May 2007 to January 2009 at the Saitama Medical University Hospital
and the participating institutes). Samples from patients with pneumonia in which a causative pathogen was identified
using criteria (1)–(3) (see Section 3.4) are shown as blue circles. The ΔCtpathogen cutoff (a red line) was defined as the
smallest ΔCtpathogen for the blue circles. The ΔCtpathogen cutoff was defined below: (A) −6 for S. pneumoniae, (B) −1 for H.
influenzae, (C) 0 for M. catarrhalis, (D) −4 for P. aeruginosa, (E) −6 for K. pneumoniae; (F) −8 for MRSA, and (G) −7 for E.
coli. Brackets indicate the target gene specific for each pathogen.
In order to  verify the hypothesis,  we first  screened S.  pneumoniae  by specific real-time
PCR (targeted to the pneumolysin gene)  in 223 pneumonia patients  (Figure 3D).  By
setting the cutoff as  the smallest  value of  ΔCtpathogen,  the samples were classified into
three groups:  (i)  samples with ΔCtpathogen  >  cutoff ( −4),  in  which case the organism was
considered to have a  high chance of  being a  causative pathogen which was called a
“therapeutic  target”;  (ii)  samples with ΔCtpathogen  <  cutoff,  in  which case the detected
organism had little  chance of  being a  causative pathogen since the pathogen-to-human
ratio has never been shown in a  causative pathogen in pneumonia;  and (iii)  samples
lacking organism detection,  in  which case the pathogen was unlikely to be a  causative
pathogen.
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Gene
(accession #)
PCR product
Sequence (5ʹ–3ʹ) Gene
(accession #)
PCR product
Sequence (5ʹ–3ʹ)
Control Foreign organisms
1 Homo sapiens 11 Mycoplasma
pneumoniae
SFTPC Fw GCAGTGCCTACGTCTAAGCTG 16S rRNA Fw AGTAATACTTTAGAGGCGAACGGGTGA
(U02948.1) Rv TAGATGTAGTAGAGCGGCACCTC (NC_000912.1)  Rv TCTACTTCTCAGCATAGCTACACGTCA
130 bp Dp CGAGATGCAGGCTCAGCACCCTC 227 bp Dp ACCAACTAGCTGATATGGCGCA
12 Chlamydophila
pneumoniae
53KD-antigen Fw GCAACCACGGTAGCAACACAAATTA
(E12535) Rv AATTGAGCGACGTTTTGTTGCATCT
Commensal organisms 364 bp Dp AGCGGCTGTCAAATCTGGAATAAAAG
2 Streptococcus
pneumoniae
13 Chlamydophila
psittaci
lytA Fw ACGCAATCTAGCAGATGAAGCA ompA Fw GTATGTTCATGCTTAAGGCTGTTTTCAC
(AE005672) Rv TCGTGCGTTTTAATTCCAGCT (X56980.1) Rv TCCCACATAGTGCCATCGATTAATAAAC
75 bp Dp TGCCGAAAACGCTTGATACAGGGAG 291 bp Dp CCAGAAGAGCAAATTAGAATAGCGAGCA
3 Haemophilus
influenzae
14 Coxiella burnetii
16S rRNA Fw TTGACATCCTAAGAAGAGCTCAGAGA Transposase Fw GTCTTAAGGTGGGCTGCGTG
(Z22806.1) Rv CTTCCCTCTGTATACGCCATTGTAGC (M80806) Rv CCCCGAATCTCATTGATCAGC
267 bp Dp ATGGCTGTCGTCAGCTCGTGTT 295 bp Dp AGCGAACCATTGGTATCGGACGTTTATGG
4 Moraxella
catarrhalis
15 Legionella spp.
copB Fw GACGGGTGAGTAATGCCTAGGA 16S rRNA Fw AGGCTAATCTTAAAGCGCCAGGCC
(U69982.1) Rv CCACTGGTGTTCCTTCCTATATCT (FR799709) Rv GCATGCTTAACACATGCAAGTCGAAC
298 bp Dp AGTGGGGGATCTTCGGACCTCA 198 bp Dp CATATTCCTACGCGTTACTCACCCGT
5 Pseudomonas
aeruginosa
16 Legionella
pneumophila
23S rRNA Fw TCCAAGTTTAAGGTGGTAGGCTG mip Fw TAACCGAACAGCAAATGAAAGACG
(AJ549386) Rv ACCACTTCGTCATCTAAAAGACGAC (S72442.1) Rv AAAACGGTACCATCAATCAGACGA
94 bp Dp AGGTAAATCCGGGGTTTCAAGGCC 264 bp Dp TGATGGCAAAGCGTACTGCTGAA
6 Klebsiella
pneumonia
17 Bordetella
pertussis
gapA Fw TGAAGTATGACTCCACTCACGGT BP485 Fw CGAGCCACTGTTTCTATTGATTGA
(M66869) Rv CTTCAGAAGCGGCTTTGATGGCTT (BX640412) Rv CGGGCCTCATCTTCGTTCAG
670 bp Dp CCGGTATCTTCCTGACCGACGA 118 bp Dp TGTGCGTGTTTTCCCCAGAGCCCC
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Gene
(accession #)
PCR product
Sequence (5ʹ–3ʹ) Gene
(accession #)
PCR product
Sequence (5ʹ–3ʹ)
7 Staphylococcus
aureus
18 Mycobacterium
tuberculosis
femB Fw TGGCCACTATGAGTTAAAGCTTGC MPB64 Fw ATCCGCTGCCAGTCGTCTTCC
(DQ352467) Rv TCATAATCAATCACTGGACCGCGA (NC_000962) Rv CTCGCGAGTCTAGGCCAGCAT
162 bp Dp CGAGGTCATTGCAGCTTGCTTACTTA 238 bp Dp CCGGACAACAGGTATCGATAGCGCC
8 Escherichia
coli
19 Mycobacterium
intracellulare
phoA Fw CGAAGAGGATTCACAAGAACATACC ITS 16-23S
rRNA
Fw AGCACCACGAAAAGCACTCCAATT
(M29670) Rv GGTCTGGTCGGTCAGTCCAA (AM709724) Rv CGAACGCATCAGCCCTAAGGACTA
94 bp Dp CGGGCCATACGCCGCAATACGCA 243 bp Dp CCTGAGACAACACTCGGTCGATCC
20 Mycobacterium
avium
16S rRNA Fw CAAGTCGAACGGAAAGGCCTCT
(M29572) Rv GCCGTATCTCAGTCCCAGTGTG
Drug resistance-related genes 257 bp Dp TACCGGATAGGACCTCAAGACGC
9 Metallo-beta-
lactamase
21 Mycobacterium
kansasii
IMP Fw GGCAGYATTTCCTCTCATTTTCATAGC dnaJ Fw ACCCGTGTGATGAGTGCAAAGGC
(AY625689) Rv AATTTGTRGCTTGAACCTTACCGTCTT (AB292544.1) Rv GTAAAGCTGACCGGAACTGTGACG
134 bp Dp ATTCTCGATCTATCCCCACGTATGCA 231 bp Dp AGGACGGACAGCGGATCAGACT
10 Methicillin-
resistant S.
aureus
22 Pneumocystis
jiroveci
mecA Fw AACTACGGTAACATTGATCGCAAC 5S rRNA Fw GTGTACGTTGCAAAGTACTCAGAAGA
(AY786579) Rv CTTTGGTCTTTCTGCATTCCTGGA (AF461782) Rv GATGGCTGTTTCCAAGCCCA
112 bp Dp AGATGGTATGTGGAAGTTAGATTGGGA 346 bp Dp CTAGGATATAGCTGGTTTTCTGCGAA
23 Nocardia spp.
16S rRNA Fw CCTTCGGGTTGTAAACCTCTTTCGAC
(DQ659898) Rv TTGGGGTTGAGCCCCAAGTTTTCA
191 bp Dp AAGAAGCACCGGCCAACTACGTGC
A database search was used to select potential DNA sequences to identify microorganisms of interest. The primers and
probes were validated using genomic DNA from the microorganism of interest as well as screened against 74 other
microorganisms [12]. Fw, forward primer; Rv, reverse primer; Dp, detection probe (TaqMan).
Table 2. Primers and probes for the real-time PCR.
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4.4. Determination of the ΔCtpathogen cutoff
We then confirmed that the primers and probes were specific to seven representative com-
mensal organisms (S. pneumoniae, H. influenzae, Moraxella catarrhalis (M. catarrhalis), Pseudomo‐
nas aeruginosa (P. aeruginosa), Klebsiella pneumoniae (K. pneumoniae), Methicillin-resistant
Staphylococcus aureus (MRSA), and Escherichia coli (E. coli)) and the human genome and were
able to quantify their cell numbers by counting the copy numbers (Ct value) for each in sputum.
The pathogen-to-human cell number ratio was measured using 533 sputum samples collected
in the past clinical study between May 2007 and January 2009 (Figure 4). Based on the
microbiological examination and its criteria (see Section 3.4), the ΔCtpathogen cutoff to discrimi-
nate the causative pathogens was determined by the smallest ΔCtpathogen value in seven
organisms (Figure 4).
4.5. HIRA-TAN system
Accordingly, we devised a PCR-based test for sputum samples that can distinguish causative
pathogens from detected commensal organisms. Moreover, combining the described PCR
system for “commensal organisms” with a PCR detection system for “foreign organisms”
constitutes the HIRA-TAN (human cell-controlled identification of the respiratory agent from
“TAN,” which means sputum in Japanese), which involved 23 PCR with organism-specific
target genes for quantifying 7 commensal organisms, 13 foreign organisms, 2 drug resistance-
related genes (DRRG), and the human specific gene (as the internal control) (Table 2). HIRA-
TAN was capable of screening 23 target genes simultaneously and diagnosing the therapeutic
targets among commensal and foreign organisms in a single assay, which was able to be
completed within 4 h. The technical details in the real-time PCR and the HIRA-TAN system
were discussed in more detail in Refs. [12, 14].
4.6. Criteria for detected organisms to be the therapeutic target by HIRA-TAN system
In the HIRA-TAN system, the cutoff value was determined for each commensal organism,
which enabled us to discriminate the bona fide therapeutic target from other commensal
organisms detected by real-time PCR,. with the assumption being that the high relative levels
of any of the given candidate pathogens would increase its likelihood of being the causative
pathogen. Thus, commensal organisms were diagnosed as the “therapeutic target” when
Ctpathogen exceeded the given cutoff value. Foreign organisms were diagnosed as the “thera-
peutic target” when detected by real-time PCR.
Technically, since opportunistic organisms, such as Pneumocystis jiroveci and Nocardia spp.,
were not normally identified from healthy individuals, they were classified as foreign organ-
isms. Methicillin-resistant S. aureus (MRSA) was judged as therapeutic target in HIRA-TAN
both when S. aureus (femB gene) was detected above −7 in the ΔCtS. aureus cutoff and when
DRRG (mecA gene) was also detected above −8 in the ΔCtMRSA cutoff altogether. IMP-pro-
ducing P. aeruginosa (multidrug resistance P. aeruginosa, MDRP) was judged as therapeutic
target in HIRA-TAN both when P. aeruginosa was detected above −4 in the ΔCtP. aeruginosa cutoff
and IMP gene was detected altogether.
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5. Materials and methods
5.1. Respiratory specimen
In Section 5, samples and their treatment will be described. Sputum, induced sputum, or
sputum obtained by intratracheal aspiration (sputum hereafter) was collected from patients
with pneumonia. The sample was homogenized by pipetting and dispensed into two tubes;
one was submitted for a standard microbiological test (microscopic examination and culture)
and the other for nucleic acid extraction and real-time PCR analysis. To assess the pathogenic
role with an appropriate sample, sputum with M2–P3 macroscopic appearance and a Cthuman
<27 (the human-specific gene with Ct (threshold cycle) value by the real-time PCR) were
studied [15]. Classification of the gross appearance of the sputum (M1, M2, P1, P2, and P3) was
according to Miller and Jones [16].
5.2. DNA preparation from sputum
There are several kit options available for DNA extraction depending on the sample type;
however, only column-based extraction has been used for most respiratory specimens due to
their viscosity [14]. The sample was diluted with an equal volume of phosphate-buffered saline
(PBS) and homogenized by vortexing. 200 μL of the homogenate was mixed with 200 μL AL
buffer (Qiagen, Tokyo, Japan) containing 20 μL proteinase K (Takara Bio Inc., Shiga, Japan),
and the resultant mixture was incubated at 56°C for 1 h. The DNA was extracted with 100 μL
TE buffer using QIAamp DNA Blood Mini Kit (Qiagen, Tokyo, Japan). The DNA concentration,
based on the absorbance, was determined in a spectrophotometer GeneQuant Pro (GE
Healthcare, Tokyo, Japan). The ratio of nucleic acid to protein absorbance (260 nm/280 nm)
was calculated as an index of the purity of DNA samples [14].
5.3. Real-time PCR
Although a variety of PCR methodologies and devices are available, an illustration of the
details of our approach is given. The final solution of the PCR contained 12.5 μL of the Takara
Premix Ex Taq (Takara Bio Inc., Shiga, Japan), 300 nM of each primer, 100–300 nM of the
fluorescence-labeled TaqMan probe, 1.0 μL of purified DNA, and deionized distilled water up
to 25.0 μL. The PCR for 23 target genes was multiplexed in 16 reactions and amplified using
in a single assay. The PCR was performed by starting at 95°C for 30 s followed by 40 cycles at
95°C for 8 s, 61°C for 25 s, and 72°C for 20 s using the SmartCycler II (Cepheid, Sunnyvale,
CA). The sequences of primer and probe were described in Table 2.
6. Practical application of HIRA-TAN system
6.1. Prospective study
We designed a prospective study to investigate the validity of the cutoff values we set up for
the commensal organisms in the HIRA-TAN system. The aim of the study was the proportion
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of samples in which ΔCtpathogen was greater than the cutoff value (diagnosed as the therapeutic
target by HIRA-TAN), compared to the proportion of the samples in which each commensal
organism was shown to be the causative pathogen (diagnosed as the causative pathogen by
microbiological methods (Table 1)). The study was performed between February 06, 2009, and
October 14, 2010, at the Saitama Medical University Hospital and other six participating
institutes. Five-hundred and sixty eight patients with pneumonia were enrolled, and the
results of the microbiological examinations were summarized in Ref. [12] and Figure 2. The
identification rates for S. pneumonia, H. influenzae, M. catarrhalis, P. aeruginosa, K. pneumoniae,
MRSA, and E. coli by the HIRA-TAN were 91.6% (87/95; 95% CI 84.1–95.6%), 96.7% (29/30; 95%
CI 82.8–99.2%), 90.9% (10/11; 95% CI 58.7–97.7%), 93.2% (41/44; 95% CI 81.3–97.5%), 80.6%
(29/36; 95% CI 64.0–89.9%), 78.1% (25/32; 95% CI 60.0–88.5%) and 87.5% (14/16; 95% CI 61.6–
96.0%), respectively (Figure 5A–G). The response of the antibiotics and the relief of pneumonia
for the cases in which such commensal organisms were the causative pathogens showed a
consistent clinical course as predicted from the results of the HIRA-TAN.
6.2. Overall identification capacity of therapeutic targets by real-time PCR-based test
Overall performance of the HIRA-TAN system to identify both the therapeutic targets
(commensal organisms judged by the ∆Ct cutoff and foreign organisms detected by the real-
time PCR) was altogether 60–70% en masse, which was comparable to what was attained by
an extensive search using multiple detection methods [10, 18, 19]. However, it is supposed to
reach its limit to identify the causative pathogens using primers and probe of only bacteria,
and for a thorough investigation, incorporating PCR systems for viruses, anaerobes, and
fungus will be required.
6.3. Beneficial aspects of PCR-based system for identifying pathogen
The most prominent feature of the HIRA-TAN is its ability to identify the causative pathogen
for the pneumonias from among the commensal organisms detected in the sputum. Clinically,
without this ability, this system would have been only partially useful, since more than half of
pneumonias are caused by commensal organisms (Figure 2). And this system does not require
the use of pathogen-by-pathogen identification methods (unique agar or a specific antibody
for an organism). The easily performed comprehensive test covers a wide variety of pathogens
in a single assay, which will reduce the time and labor spent on cumbersome procedures. The
HIRA-TAN procedure now provides a comprehensive detection system for causative patho-
gens of pneumonia.
The HIRA-TAN system can also be expanded to include more pathogens, thereby increasing
its abilities. The addition of any respiratory viruses or particular fungi to the screening protocol
is straightforward [6, 9–11, 20]. Likewise, the inclusion of other commensal organisms, such
as Acinetobacter baumannii, Burkholderia cepacia, or Stenotrophomonas maltophilia, will also be
beneficial in nosocomial pneumonia. In addition, the most challenging category is anaerobes.
Since investigating the anaerobe’s contribution to respiratory tract infection by molecular
techniques has not been attempted, indicating that setting a cutoff value for anaerobes with
HIRA-TAN system will be beneficial. Thus, the commensal organisms that have conformed to
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the scheme shown in Figure 3A–D and all non-commensal organisms become candidates,
which will make the greater detection rate by the HIRA-TAN than the current 60–70%
performance.
Figure 5. Evaluating ΔCtpathogen for each commensal organism in the prospective study (n = 568). Samples from patients
with pneumonia in which a causative pathogen was identified using criteria (1)–(3) (see Section 3.4) are shown as blue
circles, and samples from patients with pneumonia in which none of criteria (1)–(3) was met were shown as white cir-
cles. The HIRA-TAN identified the causative pathogens: (A) 91.6% (87/95; 95% CI 84.1–95.6%) for S. pneumoniae, (B)
96.7% (29/30; 95% CI 82.8–99.2%) for H. influenzae, (C) 90.9% (10/11; 95% CI 58.7–97.7%) for M. catarrhalis, (D) 93.2%
(41/44; 95% CI 81.3–97.5%) for P. aeruginosa, (E) 80.6% (29/36; 95% CI 64.0–89.9%) for K. pneumoniae, (F) 78.1% (25/32;
95% CI 60.0–88.5%) for MRSA, and (G) 87.5% (14/16; 95% CI 61.6–96.0%) for E. coli. Brackets indicate the target gene
specific for each pathogen. The 95% confidence interval (CI) was calculated using the formula for the binomial proba-
bilities by the software Mathematica Ver.8TM (Wolfram Research, IL, USA) [17].
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6.4. Drawback of newly emerged PCR system
Currently the ability of the HIRA-TAN system to determine if MRSA is the causative patho-
gen is lacking. This is largely due to the fact that the determination and establishment of the
cutoff value for a given microorganism in the HIRA-TAN system still require the conven-
tional sputum examination. To date we have not been able to determine the ΔCtMRSA cutoff,
and this will take more time and the availability of properly analyzed clinical samples to be
established. Likewise, the diagnosis of Pneumocystis jiroveci pneumonia is hardly confirmed
since the definitive diagnosis for this organism by conventional method has not been estab-
lished.
7. Conclusion
In this chapter, the principle and utility of a real-time PCR-based diagnostic test for the
causative pathogen in respiratory samples was described. Although rapid and accurate
identification of pathogens and corresponding treatment based on the microbiological re-
sults are required in the healthcare setting, the current clinical tests lacking high sensitivity
and a comprehensive approach have not been able to work these issues out. Development of
molecular techniques and their usefulness enables the detection of organisms from the clini-
cal specimens speedily as well as precisely and aids the settlement of such issues. With our
novel approach that employs the relative quantification, we successfully set up the cutoff
value to differentiate the causative pathogen from colonizing commensal organisms by
PCR, with which a real-time PCR-based diagnostic system was devised and validated
through clinical sample testing. Although this may be only one instance among many com-
prehensive systems, innovating such systems will help patients struggling with these disor-
ders in the future.
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